Allergic Rhinitis Care Gaps: Immunotherapy Access Issues
- Patients with moderate to severe allergic rhinitis (AR) often experience years of uncontrolled symptoms,worsened quality of life,and fragmented care before learning about or accessing allergen immunotherapy (AIT),according to...
- Individuals with allergic rhinitis (AR) often endure years of symptoms and multiple unsuccessful treatments before receiving appropriate care, according to a study published in 2026.
- The study revealed a considerable disease burden impacting daily life.
Patients with moderate to severe allergic rhinitis (AR) often experience years of uncontrolled symptoms,worsened quality of life,and fragmented care before learning about or accessing allergen immunotherapy (AIT),according to a new qualitative study published in JACI Global.
Allergic Rhinitis Patients Face Years of Delays, Limited Relief
Individuals with allergic rhinitis (AR) often endure years of symptoms and multiple unsuccessful treatments before receiving appropriate care, according to a study published in 2026. Researchers at [Institution Name – *to be added upon verification*] identified three key themes: a lengthy period with symptoms, repeated trials of therapies that didn’t work, and varied experiences with allergen immunotherapy (AIT).
- Prolonged Symptom Duration: Participants reported experiencing symptoms – sneezing, nasal congestion, runny nose, and itchy eyes – for years, even decades, before diagnosis.
- Barriers to Diagnosis: Delays stemmed from misdiagnosis, limited access to allergy specialists, lengthy wait times at public hospitals, and the cost of private care.
- Underestimation of Impact: Social norms often minimize AR, leading to dismissal of symptoms as ”just hay fever” by family, coworkers, and even healthcare providers.
The study revealed a considerable disease burden impacting daily life. Participants reported issues with sleep, work productivity, school performance, and social activities. Absenteeism, presenteeism, and emotional distress were common, particularly after the COVID-19 pandemic due to the social stigma associated with respiratory symptoms.
The vast majority of participants had tried over-the-counter and prescription symptomatic treatments, including oral antihistamines, intranasal corticosteroids, and eye drops. However,these provided limited or temporary relief.Concerns about medication tolerance and dependence led some to cycle through therapies or reduce usage despite ongoing symptoms. No participant reported lasting symptom control with medication alone.
While allergen immunotherapy (AIT) is the only treatment that addresses the root cause of AR, awareness of AIT was low among participants before consulting a specialist. Those who pursued AIT typically did so after years of unsuccessful symptom management. Expectations regarding AIT varied; those new to treatment often hoped for a complete cure,while those with prior AIT experience had more realistic expectations.
1[Link to original study – *to be added upon verification*]